Suven Life Sciences Ltd: Why Is It Outperforming Nifty 500?

Suven Life Sciences Ltd's latest quarterly results (Mar 2026) show

• PAT Growth YoY: -4.5% (stable)
• Revenue Growth YoY: +100.0%
• Operating Margin: -3331.0% (volatile)

Suven Life Sciences Ltd's profit is declining with an stable trend.

• PAT Growth YoY: -4.5% (latest quarter)
• PAT Growth QoQ: +54.9% (sequential)
• 3-Year PAT CAGR: -50.0%
• Trend: Stable — consistent growth pattern

Suven Life Sciences Ltd's revenue growth trend is stable.

• Revenue Growth YoY: +100.0%
• Revenue Growth QoQ: -33.3% (sequential)
• 3-Year Revenue CAGR: -20.6%

Suven Life Sciences Ltd's operating margin is volatile.

• Current OPM: -3331.0%
• OPM Change YoY: -350.0% basis points
• OPM Change QoQ: +347.0% basis points

Suven Life Sciences Ltd's long-term compounding rates

• 3-Year Profit CAGR: -50.0%
• 3-Year Revenue CAGR: -20.6%

Suven Life Sciences Ltd's earnings growth is stable with improving on a sequential basis.

• YoY Acceleration: +75.5% bps
• Sequential Acceleration: +82.5% bps
• Margin Warning: Operating margins are under pressure

Suven Life Sciences Ltd's trailing twelve month (TTM) performance

• TTM PAT: ₹-277 Cr
• TTM PAT Growth: -72.0% YoY
• TTM Revenue: ₹8 Cr
• TTM Revenue Growth: +14.3% YoY
• TTM Operating Margin: -3974.4%

Suven Life Sciences Ltd appears significantly overvalued based on our fair value analysis.

• Valuation Signal: Significantly Overvalued
• Price-to-Book: 11.9x

Suven Life Sciences Ltd's price-to-book ratio is 11.9x.

• Price-to-Book (P/B): 11.9x
• Book Value per Share: ₹22
• Current Price: ₹267

Suven Life Sciences Ltd is rated Weak with a fundamental score of 33/100. This score is calculated from objective financial metrics

• Revenue Growth YoY: +100.0% (10% weight)
• PAT Growth YoY: -4.5% (10% weight)
• PAT Growth QoQ: +54.9% (10% weight)
• Margins stable (10% weight)

Suven Life Sciences Ltd has a debt-to-equity ratio of N/A.

• Total Debt: ₹17 Cr

Suven Life Sciences Ltd's return ratios over recent years

• FY2024: ROCE -36.0%
• FY2025: ROCE -87.0%
• FY2026: ROCE -77.0%

Suven Life Sciences Ltd's operating cash flow is negative (FY2026).

• Cash from Operations (CFO): ₹-302 Cr
• Free Cash Flow (FCF): ₹-764 Cr

Suven Life Sciences Ltd currently does not pay a significant dividend (yield 0.00%).

• Dividend Yield: 0.00%
• Current Price: ₹267

Suven Life Sciences Ltd's shareholding pattern (Mar 2026)

• Promoters: 70.2%
• FII (Foreign): 0.9%
• DII (Domestic): 4.6%
• Public: 24.3%

Suven Life Sciences Ltd's promoter holding has increased recently.

• Current Promoter Holding: 70.2% (Mar 2026)
• Previous Quarter: 67.4% (Dec 2025)
• Change: +2.79% (increasing — positive signal)

Suven Life Sciences Ltd has been outperforming Nifty 500 for 2 consecutive weeks, indicating early-stage outperformance.

Suven Life Sciences Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.

Based on quantitative research signals, here is why Suven Life Sciences Ltd may be worth studying

• Currently showing mixed signals — monitor for clearer trend confirmation

Suven Life Sciences Ltd investment thesis summary:

Suven Life Sciences Ltd's forward outlook based on current data signals

• Earnings Trend: stable
• Revenue Trend: stable
• Margin Trend: volatile
• Valuation: Significantly Overvalued